Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
MedPage Today on MSN7d
Myasthenia Gravis Antibody TypesMyasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...
GMA Network on MSN20h
Sunshine Cruz diagnosed with Myasthenia Gravis autoimmune diseaseSunshine Cruz shared that she has been diagnosed with an autoimmune disease, just a few days after walking in the Bench Body ...
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
GlobalData on MSN5d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback